Senators Press Drug-Company Executives Over Prices

The hearing Tuesday signaled bipartisan support for changes that could reshape the pharmaceuticals industry

By

Leaders from seven drugmakers representing $140 billion in U.S. revenue defended their pricing in a Senate hearing that showcased bipartisan support for what would be some of the most significant changes to the industry in decades.

Executives from Johnson & Johnson, Pfizer Inc. and the other companies pushed back on some of the proposals mentioned by lawmakers, especially linking the price paid for drugs in the U.S. to their cost overseas, as the Trump administration has proposed.

...

RELATED VIDEO

High Insulin Prices Drive Diabetics to Take Extreme Measures
The price of insulin has skyrocketed over the last few decades, making it increasingly difficult for diabetics to afford. WSJ’s Jason Bellini takes a look at some of the unconventional steps Americans are taking to access the lifesaving drug.